Standard Biotools Stock Alpha and Beta Analysis
| LAB Stock | USD 1.17 0.02 1.74% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Standard Biotools. It also helps investors analyze the systematic and unsystematic risks associated with investing in Standard Biotools over a specified time horizon. Remember, high Standard Biotools' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Standard Biotools' market risk premium analysis include:
Beta 1.79 | Alpha (0.23) | Risk 4.42 | Sharpe Ratio (0.07) | Expected Return (0.32) |
Standard Biotools Quarterly Cash And Equivalents |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Standard Biotools Analysis, Standard Biotools Valuation, Standard Biotools Correlation, Standard Biotools Hype Analysis, Standard Biotools Volatility, Standard Biotools Price History and analyze Standard Biotools Performance. Standard Biotools Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Standard Biotools market risk premium is the additional return an investor will receive from holding Standard Biotools long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Standard Biotools. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Standard Biotools' performance over market.| α | -0.23 | β | 1.79 |
Standard Biotools expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Standard Biotools' Buy-and-hold return. Our buy-and-hold chart shows how Standard Biotools performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Standard Biotools Market Price Analysis
Market price analysis indicators help investors to evaluate how Standard Biotools stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Standard Biotools shares will generate the highest return on investment. By understating and applying Standard Biotools stock market price indicators, traders can identify Standard Biotools position entry and exit signals to maximize returns.
Standard Biotools Return and Market Media
The median price of Standard Biotools for the period between Fri, Nov 28, 2025 and Thu, Feb 26, 2026 is 1.42 with a coefficient of variation of 11.19. The daily time series for the period is distributed with a sample standard deviation of 0.16, arithmetic mean of 1.39, and mean deviation of 0.13. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Casdin Partners Master Fund, L.p. of 125000 shares of Standard Biotools at 1.4201 subject to Rule 16b-3 | 12/02/2025 |
2 | EY announces rollout of new physical AI platform, opening of EY.ai Lab and EY Global Robotics and Physical AI leader appointment | 12/03/2025 |
3 | Acquisition by Casdin Partners Master Fund, L.p. of 150000 shares of Standard Biotools at 1.4468 subject to Rule 16b-3 | 12/04/2025 |
4 | Contrasting Alternate Health Standard BioTools | 01/07/2026 |
5 | Standard BioTools Inc. Receives 1.35 Average PT from Analysts | 01/12/2026 |
6 | Standard BioTools Trading Up 5.6 percent Should You Buy | 01/16/2026 |
7 | Clover Health Investments vs. Standard BioTools Financial Analysis | 01/26/2026 |
8 | Standard BioTools Completes Sale of SomaLogic to Illumina | 01/30/2026 |
9 | STAND TOGETHER VENTURES LAB, CUBIT CAPITAL, 8VC, AND GSV INVEST IN TAP TO ACCELERATE AI-POWERED WORKFORCE DEVELOPMENT FOR ADVANCED MANUFACTURING | 02/10/2026 |
10 | Standard BioTools Inc. Stock Analysis Unpacking a .64 percent Potential Upside in the Healthcare Sector - DirectorsTalk Interviews | 02/13/2026 |
11 | Synergetics.ai and BorderX Lab Enter Strategic Alliance to Power Agentic Commerce | 02/17/2026 |
12 | GLOBAL OVARIAN CANCER RESEARCH CONSORTIUM AWARDS INAUGURAL AI ACCELERATOR GRANT WITH MICROSOFTS AI FOR GOOD LAB | 02/19/2026 |
13 | Disposition of 12740 shares by Hanjoon Kim of Standard Biotools at 1.15 subject to Rule 16b-3 | 02/23/2026 |
About Standard Biotools Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Standard or other stocks. Alpha measures the amount that position in Standard Biotools has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Payables Turnover | 6.05 | 7.34 | 7.91 | 5.26 | Days Of Inventory On Hand | 134.09 | 164.9 | 170.45 | 195.83 |
Standard Biotools Upcoming Company Events
As portrayed in its financial statements, the presentation of Standard Biotools' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Standard Biotools' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Standard Biotools' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Standard Biotools. Please utilize our Beneish M Score to check the likelihood of Standard Biotools' management manipulating its earnings.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Standard Biotools
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Standard Biotools Analysis, Standard Biotools Valuation, Standard Biotools Correlation, Standard Biotools Hype Analysis, Standard Biotools Volatility, Standard Biotools Price History and analyze Standard Biotools Performance. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Standard Biotools technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.